Leerink Says FDA OK of Once a Week Byetta Could Be Delayed Til Year-End '10, But Raises Price Target on Amylin (AMLN)
Tweet Send to a Friend
Leerink Swann reiterates a 'Market Perform' rating on Amylin Pharmaceuticals (Nasdaq: AMLN), adjusts valuation range to $12-14 from $12.
Leerink ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Leerink ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
